Roth 'Encouraged' by Spectrum's (SPPI) Licensing Agreement with CASI Pharma (CASI)
Tweet Send to a Friend
Roth Capital maintains a Buy rating and $15 price target on Spectrum Pharma (Nasdaq: SPPI) following news that the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
